News
ALKS
28.50
+0.53%
0.15
Alkermes Advances Orexin Program with ALKS 2680 Candidate
TipRanks · 1d ago
Weekly Report: what happened at ALKS last week (0106-0110)?
Weekly Report · 1d ago
Mizuho Securities Sticks to Its Buy Rating for Alkermes (ALKS)
TipRanks · 5d ago
Weekly Report: what happened at ALKS last week (1230-0103)?
Weekly Report · 01/06 09:07
Weekly Report: what happened at ALKS last week (1223-1227)?
Weekly Report · 12/30/2024 09:07
Weekly Report: what happened at ALKS last week (1216-1220)?
Weekly Report · 12/23/2024 09:07
Mizuho Securities Sticks to Its Buy Rating for Alkermes (ALKS)
TipRanks · 12/20/2024 18:29
Alkermes Prepares for New Flexibility Post Credit Termination
TipRanks · 12/19/2024 21:51
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt
Simply Wall St · 12/17/2024 10:05
Weekly Report: what happened at ALKS last week (1209-1213)?
Weekly Report · 12/16/2024 09:07
Analysts Conflicted on These Healthcare Names: Talkspace (TALK), Centene (CNC) and Alkermes (ALKS)
TipRanks · 12/16/2024 06:21
Tracking Baker Brothers Portfolio - Q3 2024 Update
Seeking Alpha · 12/12/2024 04:38
Insider Sale: EVP R&D of $ALKS (ALKS) Sells 61,151 Shares
Barchart · 12/10/2024 06:10
Weekly Report: what happened at ALKS last week (1202-1206)?
Weekly Report · 12/09/2024 09:07
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Biogen (BIIB) and Edwards Lifesciences (EW)
TipRanks · 12/05/2024 18:12
Alkermes To Present At Evercore ISI HealthCONx Conference; Webcast At 10:25 AM ET
NASDAQ · 12/03/2024 14:29
Alkermes Aims for Growth with Neuroscience Focus
TipRanks · 12/02/2024 22:30
Weekly Report: what happened at ALKS last week (1125-1129)?
Weekly Report · 12/02/2024 09:07
Weekly Report: what happened at ALKS last week (1118-1122)?
Weekly Report · 11/25/2024 09:06
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Seeking Alpha · 11/24/2024 14:58
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.